Related Experiment Videos
Reproducible erythroid aplasia caused by mycophenolate mofetil
K Arbeiter1, L Greenbaum, E Balzar
1Department of Pediatrics, Vienna Medical School AKH Wien, Vienna, Austria.
Abstract:
Anemia secondary to mycophenolate mofetil (MMF) was recently described in experimental animals. A clinical association between MMF and anemia has been observed, but there are no proven reports. We describe a girl with chronic graft failure who developed erythroid aplasia under immunosuppression with MMF. She showed prompt resolution when MMF was discontinued and a recurrence of this clinical course when MMF was restarted. As re-challenge with a medication is the most definitive approach for showing a direct relationship between the drug and the side effect, this case clearly demonstrates that MMF can cause erythroid aplasia.
Insights
Mycophenolate mofetil (MMF) can cause erythroid aplasia, a severe anemia. This case study confirms a direct link between MMF and this serious side effect in patients.
Area of Science:
- Hematology
- Immunosuppressive therapy
- Transplantation
Background:
- Mycophenolate mofetil (MMF) is an immunosuppressant used in transplantation.
- Anemia has been anecdotally linked to MMF, but direct causality was unproven.
- Erythroid aplasia is a rare condition characterized by the cessation of red blood cell production.
Observation:
- A patient with chronic graft failure developed erythroid aplasia while on MMF immunosuppression.
- The patient's condition resolved upon discontinuation of MMF.
- Erythroid aplasia recurred when MMF was reintroduced, establishing a clear temporal relationship.
Findings:
- This case provides definitive evidence of a causal relationship between MMF and erythroid aplasia.
- Drug re-challenge confirmed MMF as the causative agent for the observed anemia.
- MMF-induced erythroid aplasia is a significant, albeit rare, adverse effect.
Implications:
- Clinicians should consider MMF as a potential cause of erythroid aplasia in transplant recipients.
- Monitoring for anemia in patients receiving MMF is crucial.
- This finding may influence immunosuppressive strategies in certain patient populations.